Austrian Agency For Health And Food Safety

Report No: ***INS-484650-105391479-21678300***

STATEMENT OF NON-COMPLIANCE WITH GMP

Exchange of information between National Competent Authorities (NCAs) of the EEA following the discovery of serious GMP non-compliance at a manufacturer[1]

Part 1

Issued following an inspection in accordance with
Art. 111(7) of Directive 2001/83/EC as amended

The competent authority of Austria confirms the following:
The manufacturer: ***Sichuan New Hawk Biotechnology Co. Ltd.***
Site address: ***Industrial Park, Mianyang, Yanting, 621600, China***
OMS Organisation Id. / OMS Location Id.: ***ORG-100051052*** / ***LOC-100089353***

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on ***2026-04-24***, it is considered that **it does not comply with the Good Manufacturing Practice** requirements referred to in

- The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC and an appropriate level of GMP as referred to in Article 46(f) of Directive 2001/83/EC.

Note to receiving authorities: Please contact the issuing authority within 20 working days in case there are critical(2) medicinal products potentially affected by this statement.
Manufacturing Authorisation Holders directly affected by this statement have failed to comply with their obligations under Art. 46 of Directive 2001/83/EC or Art. 93(1)(j) to (l) of Regulation (EU) 2019/6 and as a consequence the Qualified Person referred to in Art. 48 of Directive 2001/83/EC and Art. 97(1) of Regulation (EU) 2019/6 is unable to perform the batch certification referred to in Art. 51 of Directive 2001/83/EC and Art. 97 (6) and (7) of Regulation (EU) 2019/6.
In exceptional circumstances there may be no objection to the Qualified Person certifying affected batches thereby allowing their release provided all of the following conditions are fulfilled:

1. Batch certification is performed in order to maintain supply of critical medicinal products only.
2. A documented risk assessment has been performed by, or on behalf of, the Qualified Person and additional actions have been implemented by the manufacturing and/or batch release site to mitigate the risks posed by the non-compliance. Note: Repeated testing alone is not normally sufficient risk mitigation but, together with other actions, can form part of a strategy commensurate with the nature and the level of risk.
3. A thorough risk-benefit evaluation has been performed for the acceptance of risk and a report prepared that takes full account of the nature of the non-compliance with the involvement of:
    - The Manufacturing Authorisation Holder and the Qualified Person of the site responsible for batch certification.
    - The manufacturing site subject to this Statement of Non-Compliance, if different from the above.

- The relevant Marketing Authorisation Holder(s).

The report has been shared with the National Competent Authorities of the countries in which distribution of the affected batches is anticipated and that any comments from those authorities have been taken into account.

4. Written confirmation has been obtained from the National Competent Authorities in whose territories the affected batches are intended to be distributed that the product is considered critical on its territory, and that there is no objection to distribution.
5. The Supervisory Authority has been informed, if different from the above, and it has not suspended or revoked the relevant Manufacturing Authorisation.
6. The affected Marketing Authorisations have not been revoked or suspended.
7. Any further conditions imposed by the Supervisory Authority and other involved National Competent Authorities are met.

---

[1] *The statement of non-compliance referred to in paragraph 111(7) of Directive 2001/83/EC and Art. 94(2) of Regulation (EU) 2019/6, as amended, is also applicable to importers.*

[2] *See Appendix 3 of the relevant procedure in the Compilation of Union Procedures.*

Part 2

Human Medicinal Products

1 NON-COMPLIANT MANUFACTURING OPERATIONS

Include total and partial manufacturing (including various processes of dividing up, packaging or presentation), batch release and certification, storage and distribution of specified dosage forms unless informed to the contrary;

1.4	**Other products or manufacturing activity**
	1.4.1 Manufacture of 1.4.1.3 Other: Manufacturing of API only(en)

Manufacture of active substance. Names of substances subject to non-compliant:
DIOSMIN(en)

3. NON-COMPLIANT MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance:DIOSMIN

3.1	**Manufacture of Active Substance by Chemical Synthesis**
	3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: Kristallisation/Crystallisation
3.5	**General Finishing Steps**
	3.5.1 Physical processing steps: Trocknen, Vermahlen, Mikronisation, Sieben / Drying, Milling, Micronisation, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	**Quality Control Testing**
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

Clarifying remarks (for public users)

The inspection was carried out in the frame of the EDQM inspection programme. The production of API Diosmin is restricted to the production in Workshop WS01. The statement of non-compliance is related to the production of the API Diosmin.

Part 3

1.Nature of non-compliance:

An on-site GMP inspection was carried out for the first time in April 2026 for the manufacturing of API Diosmin. This was an inspection carried out in frame of the EDQM´s inspection programme to assess the compliance with Part II EU GMP guidelines and the approved CEP dossier (CEP 2016-173). The inspectors identified 1 critical, 8 major, 17 other deficiencies and 4 CEP dossier / CEP holder responsibility violations. The critical finding was related to the validity and integrity of data generated in the QC laboratory using the HPLC system. Final release results for Diosmin API could not always be relied upon as the testing for related substances and assay was not always performed in accordance with the company's internal method of analysis nor the CEP dossier. Specifically, system suitability and reference standard (a) injections were not included in the sequences for multiple batch analyses. Of the 30 batches released to Europe since the beginning of 2023, 24 batches had been tested without system suitability and reference standard (a) injections in the same sequence as the sample analysis. These analyses referenced system suitability and references standard injections from different sequences carried out either before (e.g. up to 14 days) or after (e.g. up to 12 days) the sample analysis. Therefore, the sequences from which this data was obtained could not be considered as valid to support product release. Significant gaps were identified in HPLC controls, including missing system suitability tests, absent or incomplete sample receipt logs, and lack of traceability for certain batches. Documentation did not support batch classification (e.g. R&D vs production), and duplicate analyses of the same batch lacked clear differentiation, creating a risk of sample mix-ups. Additionally, procedures for data backup were incomplete, and system access rights were not managed per SOP, with inappropriate privileges granted to the QP. 8 major deficiencies were identified related to rejection and re-use of materials and recovered materials, quality management, process equipment, documentation and records, production and in-process controls, packaging and labelling of APIs and intermediates and change control.

Action taken/proposed by the NCA

Suspensionof the marketing authorisation(s)
Suspension of Marketing Authorisation

Recall of batches already released
List of Diosmin batches released to EU from 2023 to 2025: PXC03231109, PXC03231110, PXC03240438, PXC03240439, PXC03240440, PXC03240441, PXC03240442, PXC03240821, PXC03241219, PXC03250401, PXC03250508, PXC03250524, PXC03250624, PXC03250625, PXC03250809, PXC03250810, PXC03251023, PXC03251024, PXC03251025, PXC03251026, PXC03251027, PXC03251223, PXC03251224, PXC03251225,

Prohibition of supply
API Diosmin

Suspension or voiding of CEP (action to be taken by EDQM)
CEP 2016-173/Diosmin & CEP 2024-194 /Diosmin, micronized; both CEPs have been suspended by EDQM on 11 June 2026

2026-07-03

Name and signature of the authorised person of the Competent Authority of Austria

---

Confidential
Austrian Agency For Health And Food Safety
Tel:***Confidential***
Fax:***Confidential***